The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
 
Jingran Ji
No Relationships to Disclose
 
Jacqueline V Aredo
No Relationships to Disclose
 
Andrew Piper-Vallillo
No Relationships to Disclose
 
Laura Huppert
No Relationships to Disclose
 
Julia K Rotow
Honoraria - Takeda
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Array BioPharma; Lilly
 
Hatim Husain
No Relationships to Disclose
 
Susan L Stewart
No Relationships to Disclose
 
Rosemary Cobb
No Relationships to Disclose
 
Heather A. Wakelee
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Helsinn Therapeutics; Janssen Oncology; Mirati Therapeutics; Xcovery
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck; Takeda
 
Collin Michael Blakely
Consulting or Advisory Role - Amgen (I); Foundation Medicine; Revolution Medicines
Research Funding - AstraZeneca (Inst); Ignyta (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
 
Melisa L. Wong
Employment - Roche/Genentech (I)
Stock and Other Ownership Interests - Roche/Genentech (I)
 
Matthew A. Gubens
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Heron; Inivata; Takeda
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst)
 
Justin Chen
No Relationships to Disclose
 
Geoffrey R. Oxnard
Honoraria - Foundation Medicine; Guardant Health; Sysmex
Consulting or Advisory Role - Abbvie; AstraZeneca; DropWorks; GRAIL; Illumina; Inivata; Janssen; LOXO; Merck; Merck; Sysmex; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Caroline Elizabeth McCoach
Honoraria - Genentech; Novartis
Speakers' Bureau - Novartis
Research Funding - Novartis; Revolution Medicines
Travel, Accommodations, Expenses - Lilly; Loxo; Takeda
 
Zofia Piotrowska
No Relationships to Disclose
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Jonathan W. Riess
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Heron; Loxo; Medtronic; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)